Inventages Announce They Are Working with SAP to Develop the Next Generation
of Personalized Medicine Companies
Announced to coincide with the Personalized Medicine World Conference (PMWC
2013), Silicon Valley, CA
LONDON -- January 28, 2013
Inventages (a global healthcare venture capital fund backed by Nestlé)
announced today that they are working with SAP AG to integrate a comprehensive
and mechanism-based approach to disease management with best-in-class IT
frameworks to develop the next generation of personalized medicine companies.
Personalized medicine uses genetic and non-genetic information, such as
environmental factors, to individualize the prevention, diagnosis, and
treatment of disease. However to date, these solutions have typically been
fragmented and incomplete, only addressing a subset of influencing factors.
The personalized medicine solutions of the future will be holistic;
integrating a patient’s genomic information, medical history, environmental
and lifestyle factors. This holistic approach to managing disease will require
the integration of multiple data sources and the structuring and analysis of
large data volumes. This capability will be a key differentiator in ensuring
the success and longevity of a personalized medicine solution.
This collaboration between a global healthcare venture capital fund and one of
the world’s leading IT companies aims to provide emerging healthcare companies
with both capital and extensive expertise and resources. The collaboration
plans to leverage Inventages’ experience in developing highly efficacious
clinically validated products and SAP’s expertise in building and operating
complex IT platforms and ecosystems.
“Inventages has been looking at personalized medicine for several years and
consequently we recognize that the future of disease management needs to be
holistic; all of the factors that influence a patient’s health need to be
considered. Inventages and SAP are aligned in their vision to advance
personalized medicine through the use of information technology. This
collaboration plans to provide our companies with access to SAP’s unique
capabilities and resources in mobile, cloud and big data processing,” said Dr
Gunnar Weikert, Chairman and Managing Partner of Inventages.
“We are excited about this opportunity to collaborate with Inventages and
Nestlé, and combine our complementary capabilities in healthcare and IT,” said
Dr. Stefan Sigg, senior vice president, SAP HANA®, SAP AG. ”Inventages and
Nestlé bring deep unbiased expertise in healthcare technology development
including the design and running of clinical trials, as well as navigation of
the complex regulatory and reimbursement environments. We are confident that
this collaboration will help to identify and develop innovative healthcare
solutions with the goal of improving people’s lives.”
*Inventages is a global healthcare venture capital fund backed by Nestlé
*Investments are focused on highly effective, safe therapeutics and
technologies that stand to radically improve the practice of medicine.
*Particular areas of focus are chronic diseases such as gastrointestinal
disease, brain health, and metabolic disease, which constitute the major
burden on healthcare systems, as well as pediatrics, critical care and
# # #
SAP and all SAP logos are trademarks or registered trademarks of SAP AG in
Germany and in several other countries.
All other product and service names mentioned are the trademarks of their
SAP Forward-looking Statement
Any statements contained in this document that are not historical facts are
forward-looking statements as defined in the U.S. Private Securities
Litigation Reform Act of 1995. Words such as “anticipate,” “believe,”
“estimate,” “expect,” “forecast,” “intend,” “may,” “plan,” “project,”
“predict,” “should” and “will” and similar expressions as they relate to SAP
are intended to identify such forward-looking statements. SAP undertakes no
obligation to publicly update or revise any forward-looking statements. All
forward-looking statements are subject to various risks and uncertainties that
could cause actual results to differ materially from expectations The factors
that could affect SAP's future financial results are discussed more fully in
SAP's filings with the U.S. Securities and Exchange Commission ("SEC"),
including SAP's most recent Annual Report on Form 20-F filed with the SEC.
Readers are cautioned not to place undue reliance on these forward-looking
statements, which speak only as of their dates.
Tel: +44 (0)207 730 0979
Press spacebar to pause and continue. Press esc to stop.